retatrutide type 2 diabetes phase 2 results 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Pharmacological therapies for type 2

Also, Nikolaidis et al

When I first met him, in February 2025, he was 380 pounds, down 160 pounds from his heaviest, in 2020

Ozempic is also indicated to reduce cardiovascular risk in adults with T2D and established cardiovascular disease, while Wegovy is indicated for cardiovascular risk reduction in adults with established cardiovascular disease who have overweight or obesity

It is useful in individuals with poor dietary intake, chronic illness, or increased nutritional demands

These developments highlight how the industry is moving beyond a one-size-fits-all approach, exploring multiple pathways to tackle obesity and metabolic diseases